我們已在上線！ 進一步了解
NMRD

Nemaura Medical, Inc. Common Stock
NMRD

已下市

NMRD已於2024年1月4日下市。

返回排名列表
 

關於： Nemaura Medical Inc is a medical technology company developing sugarBEAT as a non-invasive, affordable, and flexible Continuous Glucose Monitor (CGM) designed for people with diabetes and pre-diabetics to manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading. SugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with an app displaying glucose readings at five-minute intervals for periods up to 24 hours.

員工： 38

醫療保健 醫療器材與用品

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%
中性
GlobeNewsWire
2 年前
Important Update on Listing Status and Strategic Direction
Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will impact Nemaura Medical's listing status on The Nasdaq Capital Market and our broader strategic direction.
Important Update on Listing Status and Strategic Direction
中性
GlobeNewsWire
2 年前
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision
Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company's request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1st, 2024, to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market.
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision
中性
GlobeNewsWire
2 年前
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth
Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce the execution of a strategic agreement for a $10 million credit facility which is expected to support the Company's strategic growth plans.
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth
正面
Zacks Investment Research
2 年前
Nemaura (NMRD) to Expand in UK With Metabolic Health Program
The latest program leverages Nemaura's (NMRD) world-first daily wear non-invasive CGM technology, providing individuals with real-time insights into their body's glucose dynamics.
中性
GlobeNewsWire
2 年前
Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
Company CEO to discuss development at 1pm EST on 15 th November 2023, at the Sidoti Virtual Investor Conference
Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
查看新聞排名
價格圖表採用Lightweight Charts™實作